Hormone receptor-positive breast cancers are typically treated with endocrine therapy, HER2-positive breast cancers are typically treated with targeted antibody or small-molecule inhibitor therapy combined with chemotherapy, and triple-negative breast cancers are usually treated with chemotherapy alone [42]. The gene discussed is ERBB2; the disease is breast carcinoma.